Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: The AGITG ATTAX2 trial

British Journal of Cancer

Volumn 108, Issue 4, 2013, Pages 771-774

  Tebbutt, N C ^a   Parry, M M ^b   Zannino, D ^b   Strickland, A H ^c   Van Hazel, G A ^d   Pavlakis, N ^e   Ganju, V ^f   Mellor, D ^g   Dobrovic, A ^g   Gebski, V J ^b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f FRANKSTON HOSPITAL   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

advanced gastric cancer; advanced oesophageal cancer; cetuximab; docetaxel

Indexed keywords

B RAF KINASE; CETUXIMAB; DOCETAXEL; K RAS PROTEIN;

ACNE; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; MIDDLE AGED; QUALITY OF LIFE; STOMACH NEOPLASMS; TAXOIDS;

EID: 84875216936     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.41     Document Type: Article

References (16)

1. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1): 21-28.
2. Carter P (2012) Merck: EXPAND Trial of Erbitux in advanced gastric cancer does not meet primary endpoint (Merck KGaA press release, 5 July 2012). Merck KGaA: Darmstadt.
3. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS (2011) A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 22(6): 1367-1373.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345.
5. Do H, Dobrovic A (2012) Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase. Oncotarget 3(5): 546-558.
6. Ferry DR, Dutton S, Mansoor W, Thompson J, Harrison M, Abbas H, Dahle-Smith A, Chatterjee A, Falk S, Garcia-Alonso A, Fyfe DW, Hubner R, Gamble T, Peachey L, Davoudianfar M, Pearson SR, Julier P, Jankowski J, Midgely R, Petty RD (2012) Phase III multi-centre, randomised, doubleblind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib). Ann Oncol 23(suppl9): ixe12.
7. Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM (2012) Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 10(1): 6-14.
8. Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, Pirker R (2011) First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with firstline chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 12(1): 30-37.
9. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30(13): 1513-1518.
10. Kim ES, Mauer AM, William Jr. WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS (2009) A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115(8): 1713-1722.
11. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A (2006) High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 6: 295.
12. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J (2011) Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in 4/ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 6(1): e15980.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792.
14. Susman E (2004) Rash correlates with tumour response after cetuximab. Lancet Oncol 5(11): 647.
15. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J (2010) Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102(3): 475-481.
16. Waddell TS, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C, Middleton GW, Wadsley J, Ferry DR, Mansoor W, Lewis Crosby TD, Coxon FY, Smith D, Waters JS, Iveson T, Falk T, Slater S, Okines AFC, Cunningham D (2012) A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 30: (abstract LBA4000).